Pharmaceuticals company Supriya Lifescience announced Q1FY24 results:
- Total revenue of Rs 134.9 crore in Q1FY24, as compared to Rs 103.7 crore in Q1FY23
- Total PAT of Rs 28.51 crore in Q1FY24, as compared to Rs 25.25 crore in Q1FY23
- Reported PAT margin of 22%
- Reported Gross profit of 64%
- EBITDA reported Rs 44.49 crore in Q1FY24, as compared to Rs 31.25 crore in Q1FY23
- Healthy EBITDA margin of 34% reported in Q1FY24
- Asian market contributed over 40% of the business, whereas Europe contributed 35%
Satish Wagh, Chairman and Managing Director, Supriya Lifescience, commenting on their results said, “The company has been resilient to the global economic conditions and has delivered a strong comeback. Our strategic business initiatives of deeper penetration in existing markets and tapping new markets, backed by our world-class R&D capabilities, have been the key growth drivers for our business. The demand from regulated markets like Europe, North America, and Latin America have surged and come back to normalcy.”